Pemphigus Vulgaris Market Size & Growth Forecast 2027–2036, By Segments (Distribution Channel, Therapy Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Pemphigus Vulgaris Market size was assessed at USD 550.73 million in 2026 and is poised to grow at a 8.69% CAGR between 2027 and 2036, exceeding USD 1.27 billion by 2036. The industry revenue for 2027 is calculated at USD 591.37 million.
Get more details on this report
Request Free Sample ReportPemphigus Vulgaris Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 41.15% of the market in 2026, benefiting from specialized healthcare infrastructure, greater disease awareness, advanced diagnostics, and access to targeted therapies.
- Improving healthcare infrastructure, rising rare disease awareness, expanding specialist networks, and increasing clinical research activity are improving diagnosis and access to advanced treatment options.
Segment Momentum
- Anti-CD20 monoclonal antibodies, particularly rituximab, held a 44.84% revenue share in 2026. Their leadership reflects growing adoption of targeted immunotherapy for disease control and long-term management.
- Hospital pharmacies accounted for 79.97% of market revenue in 2026 and remain the fastest-growing distribution channel. Their dominance reflects the need for specialist-led treatment, medication monitoring, and coordinated management of complex therapies.
Market Expansion Drivers
- Increasing awareness and early diagnosis of autoimmune disorders.
- Development of targeted biologics and therapies.
- Expansion of specialty healthcare facilities and clinical research.
Leading Market Participants
- Key companies in the pemphigus vulgaris market include Sanofi (France), Pfizer (USA), Novartis (Switzerland), AbbVie (USA), Takeda (Japan), Roche (Switzerland), Biogen (USA), Bristol Myers Squibb (USA), Eli Lilly (USA), Amgen (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 550.73 million
- 2027 Estimated Market Size: USD 591.37 million
- Projected Market Size: USD 1.27 billion by 2036
- Growth Forecast: 8.69% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Distribution Channel (Hospital Pharmacies) | Therapy Type (Anti-CD20 Monoclonal Antibodies (rituximab))
- Emerging Opportunity Segment: Distribution Channel (Hospital Pharmacies) | Therapy Type (Anti-CD20 Monoclonal Antibodies (rituximab))
Market Growth Drivers and Industry Trends
Increasing awareness and early diagnosis of autoimmune disorders
The growth of the pemphigus vulgaris market is driven by increasing awareness of autoimmune disorders and the importance of early diagnosis. Greater recognition of the symptoms associated with pemphigus vulgaris among healthcare professionals can support earlier referral, diagnostic evaluation, and treatment initiation. Improved awareness also encourages patients to seek medical attention for persistent blistering and mucosal symptoms rather than delaying care. Earlier identification can help reduce disease-related complications and increase demand for appropriate diagnostic and therapeutic interventions.
Development of targeted biologics and therapies
The growth of the pemphigus vulgaris market is attributed to the development of targeted biologics and other advanced therapeutic approaches. Traditional treatment strategies can involve prolonged immunosuppression and may be associated with significant treatment-related risks, creating demand for therapies that more specifically address the underlying autoimmune mechanisms. Advances in immunology are supporting the development of treatments designed to modulate disease-driving immune responses while improving disease control. The availability of more targeted therapeutic options is expanding treatment possibilities and contributing to the evolution of the pemphigus vulgaris treatment landscape.
Expansion of specialty healthcare facilities and clinical research
The growth of the pemphigus vulgaris market is supported by the expansion of specialty healthcare facilities and increasing clinical research focused on rare autoimmune and blistering disorders. Specialized dermatology and immunology centers can provide improved diagnostic capabilities, multidisciplinary management, and access to advanced treatment options for patients with complex disease. At the same time, clinical research is improving understanding of disease mechanisms, treatment response, and long-term disease management. These developments are strengthening the clinical ecosystem surrounding pemphigus vulgaris and supporting greater adoption of specialized care.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing awareness and early diagnosis of autoimmune disorders | 3% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Development of targeted biologics and therapies | 3% | Medium term (2–5 yrs) | North America; Europe; Spillover: Asia Pacific | High | Moderate |
| Expansion of specialty healthcare facilities and clinical research | 2.5% | Long term (5+ yrs) | Europe; North America; Spillover: Asia Pacific | Medium | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held a 41.15% share of the pemphigus vulgaris market in 2026, backed by greater disease awareness, established specialist healthcare infrastructure, and relatively strong access to diagnosis and treatment for rare autoimmune disorders. The region benefits from advanced dermatology and immunology services, greater availability of specialized diagnostic capabilities, and increasing recognition of pemphigus vulgaris as a serious autoimmune blistering disease requiring timely intervention. Improvements in diagnostic approaches and growing clinical attention toward targeted therapies are also supporting market development, while the presence of specialized treatment centers facilitates access to advanced management options. In addition, ongoing research into autoimmune mechanisms and biologic therapies is strengthening the therapeutic landscape and encouraging greater clinical interest in disease-specific treatment strategies. Continued healthcare investment, improved patient identification, and increasing emphasis on specialized care are expected to support the region’s leading position in the pemphigus vulgaris market.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing region in the pemphigus vulgaris market, driven by improving healthcare infrastructure, increasing awareness of rare autoimmune diseases, and expanding access to specialized dermatological and immunological care. Greater recognition of pemphigus vulgaris among healthcare professionals is supporting earlier diagnosis, while improvements in hospital capabilities and specialist networks are increasing opportunities for appropriate disease management. Rising healthcare expenditure and modernization of healthcare systems are further improving access to advanced diagnostic and therapeutic approaches across developing markets. Moreover, growing clinical research activity and increasing availability of innovative treatment options are contributing to greater attention toward pemphigus vulgaris management. As awareness of rare autoimmune conditions expands and healthcare providers gain greater familiarity with specialized diagnostic and treatment pathways, the region is expected to experience continued market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Advanced Biologic TherapiesThe U.S. market is centered on expanding access to targeted biologic and immunomodulatory therapies for pemphigus vulgaris, supported by specialist dermatology care and clinical research. Treatment adoption will continue to depend on efficacy, safety, reimbursement, and the availability of therapies that reduce reliance on prolonged corticosteroid use.
Germany 🇩🇪
Specialist Care IntegrationGermany's pemphigus vulgaris landscape emphasizes specialist diagnosis and treatment through dermatology centers, alongside access to advanced immunotherapies. Clinical priorities include earlier recognition of autoimmune blistering disease, steroid-sparing treatment approaches, and integration of biologics within established reimbursement and hospital-care pathways.
Japan 🇯🇵
Diagnostic and Treatment AccessJapan is focused on improving diagnosis and long-term management of pemphigus vulgaris through specialist dermatology services and established autoimmune-disease care pathways. Market priorities include timely diagnosis, access to effective immunosuppressive or biologic therapies, and treatment strategies that minimize cumulative adverse effects.
South Korea 🇰🇷
Targeted Treatment AdoptionSouth Korea's pemphigus vulgaris market is shaped by specialist dermatology management and increasing interest in targeted therapies for autoimmune blistering disorders. Priorities include improving diagnostic recognition, expanding treatment options beyond conventional immunosuppression, and supporting reimbursement access for advanced therapies.
France 🇫🇷
Autoimmune Care OptimizationFrance is prioritizing structured management of pemphigus vulgaris through specialist dermatology services and access to systemic immunomodulatory treatments. Market development is supported by efforts to improve diagnosis and treatment sequencing while increasing the role of steroid-sparing approaches for patients requiring long-term disease control.
Italy 🇮🇹
Dermatology Treatment SpecializationItaly's pemphigus vulgaris market relies on specialist dermatology expertise for diagnosis, disease monitoring, and systemic treatment. Key priorities include improving recognition of rare autoimmune blistering conditions and facilitating access to biologic and other steroid-sparing therapies through specialized clinical pathways.
Pemphigus Vulgaris Market Share (%), by Distribution Channel, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDistribution Channel Segment Analysis: Hospital Pharmacies (Largest & Fastest-Growing Segment)
The hospital pharmacies distribution channel dominated the pemphigus vulgaris market, accounting for the largest revenue share of 79.97% in 2026, while also representing the fastest-growing distribution channel. Its strong position is primarily supported by the specialized nature of pemphigus vulgaris treatment, which often requires diagnosis, treatment initiation, monitoring, and medication management in specialized healthcare settings. Hospital pharmacies provide direct access to prescribed therapies while enabling coordination between dermatologists, pharmacists, and other healthcare professionals, which is particularly important when treatment involves immunomodulatory or biologic therapies requiring appropriate clinical oversight. The channel also benefits from its ability to manage specialized medicines, maintain controlled inventory, and support prescription-based dispensing for patients undergoing long-term treatment. As awareness and diagnosis of pemphigus vulgaris improve, greater reliance on specialist-led care is expected to reinforce hospital pharmacy utilization. Increasing emphasis on treatment monitoring, medication adherence, and coordinated management of complex autoimmune disorders further strengthens the role of hospital pharmacies in facilitating timely access to pemphigus vulgaris therapies.
Therapy Type Segment Analysis: Anti-CD20 Monoclonal Antibodies (rituximab) (Largest & Fastest-Growing Segment)
The anti-CD20 monoclonal antibodies (rituximab) therapy type dominated the pemphigus vulgaris market, accounting for the largest revenue share of 44.84% in 2026, while also emerging as the fastest-growing therapy segment. Its leading position is supported by the role of B-cell-directed treatment in addressing the underlying immune mechanisms associated with pemphigus vulgaris and by increasing clinical adoption of targeted therapeutic approaches. Rituximab-based treatment can provide an important option for patients whose disease requires systemic immune modulation, particularly where conventional approaches may provide inadequate control or create challenges associated with prolonged treatment. Growing recognition of targeted immunotherapy is encouraging healthcare professionals to consider therapies that more specifically address disease-associated immune pathways. In addition, continued clinical experience with anti-CD20 treatment is supporting greater familiarity with its use in pemphigus vulgaris management. As treatment strategies increasingly emphasize disease control, reduction of relapse risk, and improved long-term management, demand for anti-CD20 monoclonal antibody therapies is expected to continue expanding across the pemphigus vulgaris treatment landscape.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Others | Hospital Pharmacies | Hospital Pharmacies |
| Therapy Type | Anti-CD20 Monoclonal Antibodies (rituximab), Systemic Corticosteroids, Conventional Steroid-Sparing Immunosuppressants, Intravenous Immunoglobulin (IVIG) - Adjunct, Topical Therapies | Anti-CD20 Monoclonal Antibodies (rituximab) | Anti-CD20 Monoclonal Antibodies (rituximab) |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Therapeutic differentiation in the pemphigus vulgaris market increasingly depends on achieving sustained disease control while reducing the burden associated with long-term corticosteroid use. Targeted B-cell depletion and other biologic therapies are important areas of development, with competitive positioning shaped by efficacy, response durability, safety, and suitability within established treatment pathways. Steroid-sparing benefits may influence prescribing decisions, but comparisons require careful consideration of clinical study designs, relapse rates, and patient characteristics. Diagnostic capabilities also contribute to market development by supporting earlier identification and more effective monitoring through serological markers. Although orphan drug designation and expedited regulatory pathways can encourage investment in treatments for this relatively small patient population, commercial prospects ultimately depend on clinical evidence, reimbursement, affordability, and access to appropriate patients.
Key companies in the pemphigus vulgaris market:
- Sanofi (France)
- Pfizer (USA)
- Novartis (Switzerland)
- AbbVie (USA)
- Takeda (Japan)
- Roche (Switzerland)
- Biogen (USA)
- Bristol Myers Squibb (USA)
- Eli Lilly (USA)
- Amgen (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Sanofi (France) | |||||||
| Pfizer (USA) | |||||||
| Novartis (Switzerland) | |||||||
| AbbVie (USA) | |||||||
| Takeda (Japan) | |||||||
| Roche (Switzerland) | |||||||
| Biogen (USA) | |||||||
| Bristol Myers Squibb (USA) | |||||||
| Eli Lilly (USA) | |||||||
| Amgen (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Celltrion | June 2025 | Celltrion received U.S. FDA approval for Truxima, its rituximab biosimilar, for treating moderate to severe pemphigus vulgaris. The approval represents the fifth adult indication for Truxima and expands Celltrion’s commercial presence in pemphigus vulgaris and the broader rare autoimmune disease treatment market. |
| Pfizer | June 2025 | Pfizer received U.S. FDA approval for Ruxience for pemphigus vulgaris injections, adding the indication alongside other rituximab-based treatment options. The approval strengthens Pfizer’s position in the pemphigus vulgaris treatment landscape and expands availability of its established biologic therapy for patients with moderate to severe disease. |
| Amgen | June 2025 | Amgen received U.S. FDA approval for Riabni for pemphigus vulgaris injections, adding the indication to its rituximab biosimilar portfolio. The regulatory approval expands Amgen’s participation in treatment of moderate to severe pemphigus vulgaris and increases the range of approved rituximab-based therapies available in the market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Pemphigus Vulgaris Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Severity | Mild Disease, Moderate Disease, Severe Disease |
| Treatment Line | First-Line Treatment, Second-Line Treatment, Third-Line & Later Treatment |
| Reimbursement Status | Publicly Reimbursed, Privately Reimbursed, Self-Pay |
Pemphigus Vulgaris Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Patient Diagnosis & Treatment Journey |
|
| Treatment Sequencing Outlook |
|
| Specialist Care Access Dynamics |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the total addressable market for pemphigus vulgaris?
How much is the pemphigus vulgaris industry expected to grow by 2036?
How is greater autoimmune disease awareness influencing pemphigus vulgaris diagnosis and treatment demand?
How are targeted therapies and specialty care reshaping the pemphigus vulgaris treatment landscape?
Why do anti-CD20 monoclonal antibodies lead the pemphigus vulgaris market?
How are hospital pharmacies strengthening their position in the pemphigus vulgaris market?
Why does North America hold the largest share of the pemphigus vulgaris market?
How is Asia Pacific emerging as a growth market for pemphigus vulgaris treatments?
What are the key competitors in the pemphigus vulgaris landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook